Fortrea Holdings enters September with an unusual split: analysts lifted targets after the last earnings print, yet shorts have quietly rebuilt to their highest level in months while options traders have swung from extreme bullishness to near-maximum caution.
The options story is the sharpest signal this week. Fortrea's put/call ratio has surged to 5.18 — more than twice its 20-day average of 2.32 — reflecting a flood of put activity relative to calls. What makes this remarkable is the direction of travel: as recently as mid-August the PCR was running below 0.12, near the 52-week floor. In the space of two weeks it vaulted to 6.62, a 52-week high, before easing slightly to the current level. That is an almost unprecedented swing in options sentiment for a mid-cap CRO name, and it coincides exactly with the post-earnings slide. The stock fell 6.2% the day after its August 3 print and is now down 7.6% over the past month to $17.72.
Short interest tells a supporting story. Bears have been adding steadily — SI has climbed to 12.8% of the free float, up 14.8% over the past 30 days and 2.4% just this week, reaching roughly 11.9 million shares short. The FINRA fortnightly figure pegs days-to-cover at 6.87, a meaningful overhang. Despite that building position, the borrow market remains loose: availability runs at roughly 1,506% — well over 15 shares available for every one currently borrowed — so there is no mechanical squeeze pressure. Cost to borrow has drifted up 22% over the week to 0.54%, and is 162% above where it was a month ago, but in absolute terms it is still a negligible friction cost. The ORTEX short score has edged up to 59.1, its highest point in the 10-day history available, suggesting the overall short signal is slowly intensifying.
The Street backdrop is more constructive than the price implies. Following the August 3 earnings report, TD Cowen raised its target to $23 (from $19) while maintaining Buy, and Citigroup lifted to $22. Truist and Evercore ISI both moved targets to $26 and $25 respectively in the days prior, keeping Outperform and Buy calls intact. The mean consensus target sits at $20.55, implying roughly 16% upside from the current price — though these analyst moves are now approaching a month old and the stock has continued to drift lower since. Barclays sits more cautiously at Equal-Weight with a $22 target; Mizuho holds Neutral with a $16 target, the only call that now sits below the market price, making it the lone cautious voice on the registered panel. EPS momentum ranks in the 68th percentile on a 30-day basis and the 78th on 90 days, suggesting the fundamental trend remains intact even if the market isn't rewarding it right now. The PE multiple has contracted about 3 points over 30 days to 18.2x, while EV/EBITDA has drifted slightly lower to 11.8x.
One entry on the ownership register worth noting: Starboard Value filed a Schedule 13D in early 2025 and was still on the register as of their last amendment in May 2025, at which point their stake had fallen from 5.4% to 3.0%. The disclosure note is important — Starboard may have continued reducing below the 5% reporting threshold without a further filing, so their current position is unknown. Separately, Wellington Management entered as a fresh holder in Q2 2026, reporting 2.38 million shares with no prior position, while FMR added a significant 2.4 million shares in the same period. Corvex Management trimmed by 1.66 million shares. The net picture is mixed — institutional turnover has been active, with new money arriving alongside existing holders reducing. BlackRock remains the dominant holder at 16.6% of shares, per their most recent filing.
The peer group offered no shelter this week. IQV was off 0.4%, ICLR dropped 4.4%, and CRL fell 5.1%. Fortrea's 3% weekly decline sits roughly in the middle of this pack, which suggests sector-wide pressure rather than an FTRE-specific dislocation. The next earnings date is flagged for October 26 — and given that the past two prints each produced single-day drops of 6-8%, the current build in put protection may simply be the market pricing in that pattern early.
What to watch: whether the put/call ratio begins to normalise as October expiries draw in fresh positioning, and whether the gap between the rising analyst consensus target and the sliding share price attracts incremental institutional buying or simply widens further into the Q3 print.
See the live data behind this article on ORTEX.
Open FTRE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
